

AREA PRESCRIBING COMMITTEE – ACTION LIST 15th OCTOBER 2015

Action Reference	Minute Reference	ACTION	OWNER	FURTHER COMMENTS	TARGET DATE	STATUS (R/A/Clear)
14/050	134/14	Draft a formal statement about the second line use of anti-TNFs for psoriatic arthritis in line with the decisions of the IFR panel.	LA	To be added to Blueteq	17.12.2015	RED ONGOING
ACTIONS FOR 2015						
15/16	33/15	<p>NICE CG Medicines Optimisation</p> <p>The CCG part completed Baseline Assessment was discussed. This is to become a standing agenda item with discussion focusing on:</p> <ul style="list-style-type: none"> • Medicines and patient safety • Patient decision aids 	PU BG PB	Provider Trusts to bring completed Baseline Assessments to the next meeting	17.12.2015	ONGOING
15/20	54/15	NTAG-Rituximab for Immune Thrombocytopenic Purpura	LA	LA to seek information on position in other NE CCG's	17.12.2015	ONGOING
15/34	72/15	NG 14-Melanoma – assessment & management	LA	Review current Vitamin D guidelines to ensure NG14 is followed	17.12.2015	ONGOING
15/36	106/15	<p>Green Bag Scheme</p> <p>BG to check with NWAS if there are any schemes running currently in the North West.</p>	BG	Possible future topic for the North West Clinical Pharmacy Forum	17.12.15	ONGOING
15/37	108/15	<p>Guidelines for the use of Feminising Hormone therapy in gender dysphoria</p> <p>Suggested changes to include local details to be incorporated into document and brought back to next meeting for approval</p>	LA		17.12.2015	ONGOING

<p>15/38 109/15</p>	<p>Guidelines for the use of Masculinising Hormone therapy in gender dysphoria Suggested changes to include local details to be incorporated into document and brought back to next meeting for approval</p>	<p>LA</p>		<p>17.12.2015</p>	<p>ONGOING</p>
<p>15/39 111/15</p>	<p>Sulfasalazine SCG PB to check with gastroenterologists whether gastro indications should be included; query re requirements for patient monitoring</p>	<p>PB</p>		<p>17.12.2015</p>	<p>ONGOING</p>
<p>15/40 120/15</p>	<p>Leflunomide SCG Final version to be brought to the next meeting for final approval</p>	<p>PB</p>		<p>17.12.2015</p>	<p>ONGOING</p>
<p>15/41 123/15</p>	<p>DRUG SAFETY UPDATE Risk of Subcutaneous Lupus Erythrematosus with PPI's – add to Prescription Pad The Cumbria yellow card report to be brought to next meeting</p>	<p>LA AL</p>		<p>17.12.2015 17.12.2015</p>	